SCHEMBL8468965

SCHEMBL8468965

N/C(=N\O)c1ccc2nc(-c3cccc(Cl)c3)cn2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 6/20 0.54
CYP3A4 P08684 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
RAB9A P51151 6/20 0.48
NPC1 O15118 5/20 0.48
MAPT P10636 3/20 0.48
ALDH1A3 P47895 2/20 0.45
KCNH2 Q12809 2/20 0.45
CYP2C9 P11712 1/20 0.45
CLK1 P49759 1/20 0.45
DYRK1A Q13627 1/20 0.45
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 5/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128050 1.00 NR4A2 (0.54) NR4A2CYP3A4HDAC1HDAC2RAB9A
SCHEMBL14046610 0.84 ALDH1A3 (0.56) NR4A2CYP3A4HDAC1HDAC2RAB9A
SCHEMBL2632253 0.78 NPC1 (0.60) RAB9ANPC1MAPTALDH1A3ALDH1A1
SCHEMBL2127102 0.78 NPC1 (0.60) RAB9ANPC1MAPTALDH1A3ALDH1A1
SCHEMBL2128047 0.78 NR4A2 (0.48) NR4A2RAB9ANPC1MAPTALDH1A3
SCHEMBL2128768 0.77 RAB9A (0.75) NR4A2RAB9ANPC1MAPTALDH1A3
SCHEMBL2126832 0.77 ALDH1A3 (0.55) CYP3A4HDAC1HDAC2RAB9ANPC1
SCHEMBL21708017 0.76 NPC1 (0.65) RAB9ANPC1MAPTALDH1A3ALDH1A1
SCHEMBL14028702 0.75 ALDH1A3 (0.58) NR4A2RAB9ANPC1ALDH1A3ALDH1A1
SCHEMBL2127099 0.75 NPC1 (0.66) NR4A2RAB9ANPC1MAPTALDH1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 NR4A2 286/4885CYP3A4 103/4885HDAC1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.